The RCVS is seeking feedback on a new draft Code of Professional Conduct.
The new Code, which would replace the existing RCVS Guide to Professional Conduct for Veterinary Surgeons, has been produced by a Working Party set up by the RCVS Advisory Committee to review the Guides for both veterinary surgeons and veterinary nurses.
According to the College, the purpose of the review, which last took place over a decade ago, is to ensure guidance to the profession and the public is clear. For example, using consistent language to distinguish between what must be done and what is advised.
The RCVS says the new Code is a short, principles-based document using the Federation of Veterinarians of Europe's Code of Conduct as the starting point. It will be supported by additional advice on specific areas of veterinary practice or issues, for example, clinical governance. It also includes:
Clare Tapsfield-Wright, Chairman of the Guides Review Working Party said: "Over the decade or so since it was last reviewed, not only has the Guide become unwieldy in places, but the way that regulators in general publish professional conduct rules has changed. Our draft new Code aims to clarify matters and bring us into line with best practice elsewhere.
"Animal owners are increasingly keen to understand the basis of what the veterinary profession considers to be good professional conduct. The new simplified Code should assist with this understanding."
The new Code, together with the consultation paper, can be downloaded at http://www.rcvs.org.uk/codeconsultation
Comments, which are welcomed from the profession and the public, should be sent by email to Christopher Murdoch, Secretary to the Guides Review Working Party, at c.murdoch@rcvs.org.uk by Friday, 24 June 2011.
A separate document is under development for veterinary nurses, which will share broadly similar underlying principles and will be the subject of its own consultation.
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
The study, which was carried out by the VetCompass programme at the RVC, in partnership with Vets Now, also found that cats are most likely to be involved in a traffic accident in the autumn.
1,407 cat road traffic accident cases that attended Vets Now clinics across the UK between December 2011 and February 2014 were analysed, with researchers finding:
Younger cats, aged six months to six years, are at the greatest risk of road traffic accidents.
Male cats are 1.3 times more at risk of road traffic accidents than female cats.
Crossbred cats are 1.9 times more at risk of road traffic accidents compared to purebred cats.
Cats are more likely to be involved in a road traffic accident in the autumn. However, they are less at risk in winter as compared to spring.
Those cats that present with abdominal or spinal injuries are more likely to die, as are those that present with an increasing count of injuries.
RVC veterinary epidemiologist and VetCompass researcher Dr Dan O’Neill said: "One of the scariest times for any cat-owner is when they first start to let their cat go outside unattended. Owners of younger, and especially male, cats need to be especially vigilant. These results help owners to understand the true risks and therefore assist these owners to make the best decisions about if and how they let their cats go outside."
Dr Amanda Boag, Clinical Director of Vets Now, said: "We are very proud to have worked with VetCompass to ensure this important information about risks to our pet cats is made available to vets and the public. Working with our partners such as the RVC, we are committed to ensuring our large clinical database is used to help advance veterinary knowledge and understanding of emergency and critical care practice."
The full paper entitled 'Epidemiology of Road Traffic Accidents in Cats attending emergency-care practices in the UK' is published in the Journal of Small Animal Practice.
Developed by Italian tech company, Otech Industry srl, the Onemytis 2 uniquely uses gas ionisation to vaporise tissue at lower temperatures and, claims Excel, with greater precision than is possible with conventional electrosurgery.
The knife works by a strong electromagnetic field through air. This releases plasma which vaporises tissue at a maximum operating temperature of 50°C (compared to more than 118°C in conventional electrosurgery).
During surgery, the electrode does not touch the patient. Plasma is formed when it is between 1 and 2 mm away from the patient, depending on the power setting. This means the surgeon does not apply any pressure when creating an incision, allowing greater precision.
The Onemytis range starts from £4500 +VAT.
West Sussex first opinion vet, Julian Hoad, Head of Crossways Veterinary Group, started using Onemytis last year for a range or procedures including laparoscopic surgery and the removal of masses, often without the need for a general anaesthetic.
Julian said: "I’ve used electrosurgery for 20 years and this is an order of magnitude better. It is more precise, more reliable and results in a much better healing surface."
"I recently removed an enlarged lymph node. The mass was around the mesenteric root. Because Onemytis is so precise I was able to dissect around the blood vessels, removing tissue that was attached to them with no blood loss. Onemytis is also excellent for removing epulides. It cuts though gingival tissue with very limited burning and produces very good, pain-free healing."
"I now routinely use it for performing nostril widening surgery in brachycephalic dogs; it reduces surgery time dramatically and completely abolishes bleeding in most cases."
"I have also used it to remove a large mass from a dog’s spleen and, by using a combination of Onemytis and Ligasure, managed to do so with a total blood loss of less than 2 ml."
Steve Hayden, Director at Excel Lasers, said: “We are delighted to be bringing Onemytis 2 to the UK. An important part of our role is to identify the technological innovations we think are most likely to help vets and their patients and Onemytis really stands out. The feedback we have had from our clients has been extremely positive and we think it has a fantastic future in veterinary surgery.”
To find out more about Onemytis 2 and watch videos of it in action, visit: https://www.excellasers.com/airplasma/
Anna, who has been with the Hertfordshire-based referral centre for seven years, is now an RCVS, EBVS and American Specialist in Small Animal Internal Medicine.
She graduated from The University of Liverpool in 2007 and spent four years working in general practice in Kent.
She then went on to complete a rotating internship, followed by a residency in Small Animal Internal Medicine at the Royal Veterinary College where she gained her Master’s degree and Diploma.
Whilst enjoying all aspects of Internal Medicine, she has special interests in endocrinology and haematology. The latter, combined with her love for cats, has fuelled her interest in feline transfusion medicine.
Anna said: “I am delighted to have been appointed as Head of Internal Medicine at Davies.
“The Internal Medicine team are the detectives who work to establish a diagnosis, and we often have the added bonus of working closely with other disciplines in our multi-disciplinary environment.
"It is a challenging and highly rewarding service, with a wide variety of cases and I am delighted to work with a first-class team of clinicians and nurses.”
Spread over two floors, the 3,300 sq ft flagship practice is unusually large for a London clinic, and has a dedicated dental suite and laboratory, as well as six spacious and bright consulting rooms.
Notably absent from the practice are a reception desk and continuously ringing telephones.
Instead, customers receive a warm welcome in the members’ area, with separate spaces for cats and dogs.
Shades of lilac on the walls have been carefully chosen to keep animals calm, while a pick and mix wall filled with toys and treats is designed to help pets develop positive associations with vet visits.
Co-founders Russell Welsh MRCVS and online estate agent entrepreneur Daniel Attia say that a large portion of Creature Comforts’ customers have signed up as ‘All Access’ members, paying £20 per month to get unlimited access to expert care from vets and nurses.
This includes as many consultations as they need, annual vaccinations and discounted routine treatments e.g. 50% off microchipping.
The remainder have opted to pay as they go for treatment.
Creature Comforts’ chief veterinary officer, Dr Simon Hayes, says: “One of the biggest problems with UK veterinary care is that, due to the expense of consultations, pet owners are understandably reluctant to book in to see a vet until their animals are really sick.
"With a subscription model that includes unlimited consultations, we’ve removed the cost barriers to accessing expertise easily and quickly, so pets are seen more frequently, and conditions can be identified and treated earlier in the disease process, meaning a vastly better outcome for pets and hopefully greater financial savings over their lifetime, too.”
Simon added: “Many people comment on the peace and quiet.
"The absence of phones ringing or receptionists permanently on calls is unusual.
"But because our customers book in, submit queries and request medications via our app, we don’t need these things.
"While our virtual care team can take calls, they’re not based in the practice.
"This frees up our people to welcome customers and make a fuss of their pets so we can turn what has long been a stressful appointment into a positive experience.
"People have told us their pets, who trembled and cried at their previous vet, are now pulling to come inside because they know they’re going to get a treat and lots of attention.
"We’re still doing all the things vets do, in terms of offering excellent care, expertise and advice, but the entire experience around it has been totally transformed.”
Creature Comforts’ third site, also in London, will open towards the end of this year, and the company is keen to hear from veterinary surgeons, nurses and others who may be interested in upcoming vacancies.
The new products are:
Leon Wright, Managing Director, said: "At Vet Direct, we’re always looking for ways to improve our service – making small changes which will have a big impact on the levels of care our clients can provide.
"We know that vets, veterinary nurses and practice managers don’t always have the time to try out new products before purchasing, and that’s why our dedicated team of sales staff test every item before adding them to our catalogue - ensuring that we only stock the highest quality products."
For more information on any of the new products, visit www.vet-direct.com or call 0800 068 3300.
Matt Yarnall from Boehringer Ingelheim said: "This is fantastic news for Bovela which offers a truly unique and innovative way of controlling BVD in a herd, something that is now clearly being appreciated by farmers and vets alike."
The company says over 5 million doses of Bovela have now been sold across Europe2 showing how quickly farmers have understood the benefits of a single dose vaccine that provides a full 12 months of live vaccine protection.
Matt added: "Feedback we have from vets and farmers throughout Europe shows two main things. Firstly, for those who haven’t controlled BVD before, there is the realisation of how much better herd health can be and secondly, for those who have previously struggled with multiple primary course vaccines or those that should be boosted every six months, there is relief at Bovela’s easy-to-follow regime."
References
Katie, who works at Milbourn Equine, is now preparing with her horse Templar Justice, or TJ for short, to take part in what is widely acknowledged to be one of the world's most difficult equestrian events.
Last year, she competed at the Burghley Horse Trials and was voted "Amateur Rider of the Year" by Horse and Hound magazine.
Katie says she is determined to build on that success with a strong showing at Badminton: "The Burghley Horse Trials were amazing last year. I was so excited to be there and it went so well. To now be competing at Badminton will be an awesome experience.
"It’s one of only six 'five-star' equestrian events in the world and to compete there really is my dream come true."
As part of the programme, BEVA is giving the coaches workshops, discussion forums and online toolkits to develop their mentoring skills. Having been trained by a specialist mentoring professional, the coaches are then paired with recent graduates to give them guidance and support during the foundation years of their careers.
The project, called 'Leg Up', has been driven by BEVA President Renate Weller, and is being trialled over the next 12 months before being rolled out more widely.
Renate said: "All professionals, but especially new graduates need support in navigating their journey through their chosen career.
"With the veterinary industry’s rapidly changing landscape and rising concern around wellbeing, consistent support and guidance have never been more relevant."
Coaching is open to BEVA concessionary members who have graduated within the past three years. They will be able to self-select a preferred coach on a first come, first served basis from the Leg Up section of the BEVA website.
Renated added: "To date access to targeted careers support has most often depended on where you work and who you know. We hope the scheme will encourage and support those entering the profession, giving them the opportunity to discuss their training, development, career progression and self-care with trained professionals who were once in their shoes."
To find out more and to sign up for the Leg Up programme visit https://www.beva.org.uk/Careers/Leg-Up
Merial Animal Health has launched Locatim, an oral antibody supplement to aid calf scour management.
Manufactured from the colostrum of high health status cows that are hyper-immunised against E.coli, rotavirus and coronavirus, Locatim contains a guaranteed concentration of specific antibodies to enterotoxic E.coli F5 (K99).
Merial says that when given alongside the dam’s colostrum, Locatim provides enhanced protection against infection, reducing calf mortality due to neonatal diarrhoea caused by E.coli F5 (K99), and helping to protect calf health during the critical rearing period.
According to the company, a single 60ml oral dose provides direct transfer of these specific antibodies, giving local protection within the digestive tract and systemic protection following absorption through the intestinal mucosa.
For optimal absorption Locatim should be administered during the first four hours of life, but it can be given up to 12 hours after birth.
Locatim can be administered to every calf born during an outbreak of scour; at times of peak calving, when environmental challenge is high; or it can be used to enhance protection in individual calves identified as being at high risk of disease due to factors such as dystocia, weakness or the poor quality of the dam’s colostrum.
For information on purchasing stock contact your local Merial Animal Health territory manager.
Dechra says the ability to split Prednicortone into 1.25 mg doses is particularly useful when used alongside Zycortal, the only licensed treatment for canine Addison’s disease in Europe.
Dechra Brand Manager Carol Morgan said: "Dogs with primary Addison’s disease have insufficient levels of natural mineralocorticoids (primarily aldosterone) and glucocorticoids (primarily cortisol). Zycortal contains DOCP, a synthetically produced steroid hormone, which acts in a similar way to aldosterone.
"It causes sodium retention and potassium excretion, helping to maintain water balance but Zycortal only replaces the mineralocorticoid. Therefore, a daily oral glucocorticoid treatment, such as Prednicortone, is needed to address the cortisol deficiency, alongside Zycortal.
"The amount of glucocorticoid administered should be adjusted to the individual dog’s need and it is likely that the dose required will be reduced over time."
She added that a combined approach of Zycortal and Prednicortone allowed independent dose titration of both mineralocorticoids and glucocorticoids.
"The advantage of prescribing the two treatments is that the dosage for each component can be tailored to an individual animal’s response. This leads to a reduction in the side effects usually associated with over-supplementation of glucocorticoids."
There are 250 tablets in a pack and Prednicortone offers accurate dosing using a double divisible SmartTab format and accurate dispensing via blister packs. The flavoured tablets also encourage easy oral administration.
For more information, visit www.dechra.co.uk.
This was the sixth time that Mr Warwick Seymour-Hamilton had applied for restoration after being removed from the Register in June 1994, the reasons for which related to the condition of his practice premises and his record-keeping following an inspection by the RCVS. His most recent restoration hearing took place in May 2017.
In his application Mr Seymour-Hamilton said that he wanted to be restored to the Register to aid his research into herbal medicines and, during the course of the hearing, he also challenged some of the evidence given to the Committee in the June 1994 hearing. In particular he challenged the assertion that his practice was open when it was inspected by the RCVS as, he submitted that, he had retired three weeks’ prior to the inspection due to ill-health.
Mr Seymour-Hamilton told the Committee that he did not wish to return to clinical practice but wished to restore his membership of the RCVS in order to prescribe his own herbal treatments and to obtain peer review that would allow his treatments to be licensed. Furthermore, he produced, during the hearing, a continuing professional development (CPD) record card in which he had logged 1,438 hours of CPD in 2017.
In considering his application for restoration the Committee dismissed his challenge to the details of his original hearing in June 1994.
Ms Judith Way, Chairing the Committee and speaking on its behalf, said: "The Committee has noted that this issue is ancient. It is not for this Committee to consider it. Moreover the finding of the Committee represents a determination which was not challenged by the applicant until one of the more recent restoration applications. He never appealed it. Nor did he attend at the original hearing. It acknowledges that the premises could well have been closed given their condition, but whether they were or not is not for it [the Committee] to decide. It is quite possible the applicant has persuaded himself of the position. This is not an issue which is a persuasive factor in this application."
Regarding Mr Seymour-Hamilton’s contention that he would use his RCVS registered status to further his research into herbal treatments Ms Way said: "The Committee accepted there were no direct public protection issues which caused it concern, although it did retain some anxiety that the applicant’s commitment to herbal medicine could govern the way in which he would wish to care for an animal. A more rounded veterinary approach, which involved a full evaluation of an animal’s condition, a coherent diagnosis and a subsequent discussion about treatment with the client is called for."
Turning to his CPD she added: "His CPD now has a bias for herbal medicine as does his extensive reading. The Committee was not satisfied that his skills are up-to-date and that he could practise veterinary medicine safely. The Committee was not satisfied that he would approach a sick animal with the full and rounded approach required of a veterinary surgeon. Nor did his confidence in this regard allay the concerns of the Committee. He expressed belief in himself on the basis of his practice which came to an end some 24 years ago."
The Committee did acknowledge that Mr Seymour-Hamilton’s removal from the Register had a considerable impact on him and that, not only is he ashamed of it, but he believes it is frustrating his ability to advance the cause of herbal medicine.
In conclusion, Ms Way said: "Taking all these matters into account, the Committee has concluded that the applicant has not satisfied it on all of the evidence that he is fit to be restored to the Register and so this application is refused."
The course will be led by Dr Jon Hall, a European Specialist in Small Animal Surgery and Dr Danielle Gunn-Moore, an RCVS-recognised Specialist in Feline Medicine, supported by RVN Ms Claire Dorey-Phillips. It will take place at Improve’s new practical training facility in Sheffield in January 2019.
Improve says the programme will equip delegates with a full understanding of the causes of FLUTD and help them to advise owners with cats suffering from the condition in order to improve long-term outcomes. It will also provide a comprehensive overview of the nursing and medical options to treat feline idiopathic cystitis (FIC) and other causes of FLUTD including infection, calculi and neoplasia. The range of appropriate surgical methods to treat ureteral obstructions will also be covered, along with the post-operative nursing care, to ensure that delegates feel ready to perform a variety of bladder surgeries with confidence.
Juliet Pope MRCVS, Veterinary Operations Manager at Improve International (pictured right), said: "Treating patients with FLUTD is a team effort so we’re offering a special rate for a vet and nurse attending from the same practice though both vets and nurses can still, of course, book independently. The cutting-edge programme will be highly interactive and we aim to send delegates back to their practices with a revitalised approach to these tricky cat cases."
For further information visit www.improveinternational.com or email enquiries@improveinternational.com or call 01793 759159.
The proposed framework has grown out of the VN Futures research project, run jointly with the BVNA, which identified developing a structured and rewarding career path for veterinary nurses as one of the key demands of the profession.
It has been developed by the VN Futures Post-Registration Development Group in conjunction with the RCVS Veterinary Nurses Education Committee and Veterinary Nurses Council.
The College says the proposed framework is designed to provide accessible, flexible and professionally relevant post-registration awards for veterinary nurses in order to provide an enhanced level of veterinary nursing practice, while also providing specific modules that veterinary nurses at all career levels can study independently for their continuing professional development (CPD).
Julie Dugmore, Director of Veterinary Nursing at the RCVS, said: "One of the strongest messages that came out of the research we conducted with the British Veterinary Nursing Association prior to the publication of the VN Futures Report was that there was a need for a more structured and rewarding career path for veterinary nurses.
"Throughout the VN Futures roadshow events nurses felt they were often entering a career cul-de-sac after a certain amount of time in practice and so the need for further post-registration qualifications which promote excellence and recognise advanced knowledge, skills, competency and experience in designated areas were strongly expressed.
"We have taken this feedback and developed it into a comprehensive framework for two defined post-registration qualifications and are very interested in hearing what both veterinary nurses and veterinary surgeons have to say about all aspects of what we are proposing.
"Once we have collated the responses, we will incorporate the feedback into the framework for further consideration by the relevant committees and VN Council. The eventual aim is that these qualifications will, once sufficiently bedded in, lead to the development of an Advanced Veterinary Nurse status so that members of the VN profession with the sufficient skills and experience will get the recognition they truly deserve."
The two new qualifications included in the framework are a Graduate Certificate in Advanced Veterinary Nursing and a Postgraduate Certificate in Advanced Veterinary Nursing. Details of the courses’ structure, candidate assessment criteria, accreditation standards, student support, candidate eligibility rules, the RCVS enrolment process and the procedures for certification will be set out in a framework document as part of the consultation process.
The document also includes a prospective list of designations for the two courses covering areas of advanced veterinary nursing knowledge such as wellness and preventative health; rehabilitation and physiotherapy; anaesthesia and analgesia; triage, critical care and emergency nursing; pharmacology; animal welfare; education and teaching; management and leadership; research; and, dentistry.
The consultation will be launched in early July with an email sent to all veterinary nurses and veterinary surgeons containing a link to the survey and asking for their views on the proposals. Details of the consultation, once launched, may also be found at www.rcvs.org.uk/consultations
The VN Futures Report is available to download from www.vetfutures.org.uk/vnfutures
The committee heard five charges against Dr Davies at a resumed hearing of an inquiry which was originally adjourned in January and then July 2018. The decision was made, at both the 2018 hearings, to postpone the final decision on the sanction.
The first two charges against Dr Davies related to convictions for drink driving in March 2014 and October 2015 for which she received driving bans of 17 and 45 months.
The third charge related to her breaching a number of undertakings she had entered into as part of the College’s Health Protocol, including her consuming alcohol on four occasions between May 2015 and January 2016 and missing a pre-arranged appointment with a consultant psychiatrist appointed.
The fourth and fifth charges related to being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016 which was also in breach of her undertakings under the Health Protocol.
At Dr Davies' first Disciplinary Committee hearing in January 2018, she admitted all five charges against her and also accepted that her conduct was disgraceful conduct in a professional respect.
The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At the conclusion of its hearing on 23 January 2018 the Committee decided to postpone its decision regarding sanction for six months on the basis of Dr Davies’ entering into undertakings, including not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement and to undergo blood and hair tests for alcohol consumption every two months.
At the resumed hearing on 30 July 2018, Dr Davies’ Counsel submitted on her behalf that she wished to return to practise and the Committee reviewed evidence that she provided to demonstrate she had complied with her undertakings.
However, the Committee retained concerns about Dr Davies' return to practise and therefore required her to identify a veterinary surgeon who would agree to act as her mentor, noting that the mentor would have to be acceptable to the College as someone suitable to act in that capacity.
The Committee also required the continuation of the requirements for abstinence from alcohol and the programme of blood and hair testing.
A further requirement of the Committee was that Dr Davies should make a disclosure to any new employer of her appearances before the Committee in January 2018 and in July 2018 and of the decisions it made.
The final requirement of the Committee was that the respondent should not accept a ‘sole charge position’ at any time during her employment during this next period of postponement of sanction. The Committee then directed that the hearing be postponed for a further 12 months.
The Disciplinary Committee resumed its inquiry on 7th August 2019, when Dr Davies submitted documentary proof and medical records to demonstrate she had complied with all her undertakings given at the last hearing. The Committee also heard from Dr Davies’ appointed veterinary mentor who provided a statement that concluded that she no longer needed monitoring or supervision.
The Committee then considered what sanction to impose on Dr Davies.
Ian Green, chairing the Committee and speaking on its behalf, said: "The view of the Committee is that the respondent has to date overcome her addiction to alcohol and, given that her competence as a practising veterinary surgeon is not disputed, that she should therefore be permitted to return to her chosen profession. However, in the judgment of this Committee the seriousness of the offences to which the Respondent has pleaded guilty means that a sanction of “No Further Action” cannot be justified."
The Committee therefore decided that the most proportionate sanction was for Dr Davies to be reprimanded as to the conduct she admitted at previous hearings and that she be warned as to her future conduct.
Ian added: "The respondent must understand that she has been given an opportunity to prove that, for the remainder of her time in practice, she can meet the high standards expected of all registered veterinary surgeons from both other practitioners and from members of the public who entrust the care and treatment of their animals to members of this profession."
Zoetis says Lokivetmab targets and neutralizes canine interleukin-31 (IL-31), a cytokine associated with atopic dermatitis which sends the itch signal to the brain.
The company has submitted an application for marketing authorisation of the product, which is conditionally licensed in the US and Canada under the name Canine Atopic Dermatitis Immunotherapeutic, in the European Union.
The new data was presented at the 8th World Congress of Veterinary Dermatology (WCVD).
Supporting the efficacy of Lokivetmab in canine AD, Zoetis presented the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) and other clinical signs associated with atopic dermatitis in dogs.
Veterinary investigators at 15 clinics enrolled 245 client-owned, live-at-home dogs with chronic atopic dermatitis. Lokivetmab or a placebo was administered by subcutaneous injection on day 0, and efficacy was evaluated periodically over 56 days. Dog owners assessed their dog’s pruritus using a visual analog scale (VAS), and investigators assessed the associated skin lesions using Canine Atopic Dermatitis Extent and Severity Index-03 (CADESI-03) scores.
Lokivetmab, injected once subcutaneously, provided dose-dependent improvement in owner-assessed pruritus and clinician-assessed CADESI-03 scores for four to six weeks in dogs with atopic dermatitis.
Zoetis also presented results of a randomized, double-blind, placebo-controlled trial to assess the safety of lokivetmab at the nominal dose tested of 1 mg/kg (range, 1-3.3 mg/kg) in the treatment of canine atopic dermatitis. Veterinary surgeons evaluated 245 client-owned, live-at-home dogs with chronic, naturally-occurring atopic dermatitis. These dogs were randomized at a 2:1 ratio to receive two monthly injections of lokivetmab (162 dogs) or placebo on days 0 and 28.
No immediate hypersensitivity reactions were observed and there were no clinically important differences in clinical pathology results. No apparent adverse drug interactions were reported. Dogs studied were taking a wide variety of medications, which is important because multimodal therapy is commonly prescribed for dogs with atopic dermatitis. Adverse events were reported at a similar frequency between the groups.
The charity says that it had already been suffering a period of 'dire financial constraints' and the economic effects of coronavirus are now having a direct effect on funding.
The charity's Trustees and Executive Committee is still trying to find emergency funding to try and save the organisation, failing which it will close on the 31st March.
The British Equine Veterinary Association has published the results of a survey it commissioned which found that horse vets in the UK are probably at greater risk of injury than any other civilian profession, including the prison service.
For the study, which was conducted by the Institute of Health and Wellbeing and the School of Veterinary Medicine at the University of Glasgow, 620 equine vets completed a work-related injuries questionnaire. The results of the study indicated that an equine vet could expect to sustain between seven and eight work-related injuries that impeded them from practicing, during a 30-year working life.
If the 620 respondents were representative of the rest of the profession, the injuries they reported would equate to 26,452 per 100,000 equine vets in employment per year. That compares with 10,760 for people working in the prison service, 8,700 for policemen below the rank of sergeant, 6,980 for welders, metal formers and related trades, and 4,760 for construction workers.
Participants were asked to describe their worst-ever injury. Most were described as bruising, fracture and laceration, with the most common site of injury being the leg (29%), followed by the head (23%). The main cause of injury was a kick with a hind limb (49%), followed by strike with a fore limb (11%), followed by crush injury (5%). Nearly a quarter of these reported injuries required hospital admission and notably, 7% resulted in loss of consciousness. The most common reason for the examination during which the injury occurred was foot lameness, followed by dental and female reproductive.
BEVA Past-President Keith Chandler said: “We were shocked to discover the extent of the injuries sustained. Of greatest concern is the number of vets who suffered head injuries and unconsciousness. These injuries appeared to be more common when certain procedures were being performed, such as endoscopy of the upper respiratory tract, when vets are often only partly sighted while using examination equipment, or during wound management and bandage-changes, where vets are often crouched-down for long periods, next to the patient.”
38% of the ‘worst’ injuries occurred when the vet was working with a ‘pleasure’ horse and most frequently (48% of all responses) the horse handler was the owner or the client at the time of the injury. Whilst the number of laypersons or handlers injured at the same time was low, Tim Parkin, vet and lead researcher, pointed out: “This work should act as a wake up call to all involved in the training, employment and engagement of equine vets. The risks associated with handling and working with horses should be the primary consideration for equine vets and horses owners alike, every time a horse is examined or treated. In addition, the experience of the horse handler should be considered when undertaking riskier procedures.”
David Mountford, Chief Executive of BEVA said: “The results are very concerning and justify a careful prospective scientific quantification of the risks. In the short term, knowledge of these risks allows us to better inform all vets who work with horses. In turn vets will be able to inform horse owners, horse-keepers and trainers of the risks, and this may provide justification for having trained assistance on-hand or the more extensive use of sedative drugs in practice, potentially reducing the risk of injury.
"The British Equine Veterinary Association will now look to work with the Health and Safety Executive, Veterinary Schools, large employers of vets in the UK and our members to help develop policies to mitigate the risk of serious injury for vets working with horses.”
Photograph courtesy Towcester Veterinary Centre
CVS says that in the USA, the veterinary profession is the fifth highest profession for non-fatal injuries, with equine veterinarians sustaining an average of eight serious injuries during their career.
‘The context, consequence and prevention of veterinary workplace injuries: a qualitative and quantitative study in the UK’ will be undertaken at the University of Liverpool in collaboration with CVS colleagues as part of its Clinical Research Awards.
The study will run for three years, supported by £74,400 of CVS funding.
The research will investigate what veterinary injuries are, what context they occur in and what their consequences are.
It will look to highlight areas of the profession where injury prevention training and strategies can be developed and adopted to improve the safety of working in veterinary practice.
For the first phase, University of Liverpool researchers have rolled out the largest ever survey to explore veterinary workplace injuries with over 5,000 CVS staff UK-wide.
The survey investigates how veterinary professionals define injuries, their specific causal mechanisms, and why individuals do or do not report injuries or seek medical treatment.
The survey will be followed by an independent audit of CVS’ accident reporting system.
The results of these two activities will lead to the development of a suite of industry leading ‘open access’ educational tools aimed at promoting injury awareness and prevention to help drive behaviour change and support injury avoidance.\
The research project is being led by Dr. John Tulloch, a Research Fellow and European Specialist in Veterinary Public Health, at the University of Liverpool.
Collaborators include CVS Head of Health and Safety Rebecca Jackson and Director of Learning, Education and Development Dr Martin Whiting.
John said: “Injuries that occur within veterinary practice can tragically at times be life-changing and are often avoidable.
"Currently we do not know some critical details that would help to improve safety within the veterinary workplace.
"If we can better understand these details, we will be able to develop and strengthen prevention measures through policy, education, and training.
"We anticipate that this project will result in safer workplaces within the wider veterinary community and, indirectly, in improved animal treatment through a fitter, healthier and safer profession.”
The British Veterinary Association has welcomed the tightening up of sales of veterinary medicines on the internet but has expressed disappointment that the advertising of antimicrobials to farmers will continue.
The Veterinary Medicines Directorate has today published its response to the public consultation on the Veterinary Medicines Regulations, which are updated every year.
The new Regulations, which come into force in April 2011, introduce new controls on internet pharmacies meaning that only approved websites will be legally allowed to dispense and supply veterinary medicines. The controls will come into force in April 2012 and the BVA supports the use of a logo on approved websites to help consumers buy medicines from reputable sources.
The BVA has previously expressed concern that pet owners could inadvertently buy counterfeit veterinary medicines online and urges veterinary clients to seek advice from their vet and only buy from UK-based companies.
Harvey Locke, President of the BVA, said: "Without proper regulation online pharmacies could be sourcing drugs from overseas and selling counterfeit medicines that look genuine to unsuspecting pet owners. These medicines are placebos at best and dangerous at worst.
"We therefore welcome the VMD's decision to clampdown on irresponsible online retailers and provide a clear logo for approved websites that will give pet owners confidence.
"We have also asked the VMD to put a stop to the increasing problem of prescription fraud and we hope the tighter regulation announced today will be a step towards achieving that aim.
"However, we would urge all pet owners to continue talking to their vet about sourcing medicines from the internet to make sure the right drugs are bought and administered correctly."
In light of increasing concerns about the growth of antimicrobial resistance the VMD's consultation canvassed views on restricting the advertising of antimicrobials to farmers. The BVA says it supported a ban on advertising as a sensible approach to the responsible use of antimicrobials, and is disappointed that the VMD has decided not to go ahead with it. Mr Locke said: "New antimicrobials are heavily advertised by pharmaceutical companies to vets and farmers so it is vital that the message of responsible use is not lost.
"Antimicrobial resistance is a serious issue for both animal and human health and we are disappointed that the VMD is not restricting the advertising of these products to farmers. The pharmaceutical companies must now undertake to advertise responsibly.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets and farmers should work together to ensure antimicrobials are used prudently and responsibly."
Some 150 practices currently use Vidivet, which was set up by Ben Sweeney MRCVS (pictured) in 2020.
He said: “I started VidiVet as I wanted people to be able to access high quality, impartial care for their pets that allows them to make more informed decisions around their treatment with expert information, rather than resorting to the internet.
"As a vet I also wanted to make life easier for those working within veterinary practices.
"VidiVet relieves part of the burden veterinary practices face by offering a trusted digital triage service for their clients.
"Our digital service can provide a helpful extension to a practice which dramatically reduces admin and saves time for the in-house team.
"Crucially, we offer peace of mind and reduce anxiety for pet owners, and with over 96% of VidiVet out of hours calls redirected to the pet owner’s registered vet, it can really enhance the practice bond by using digital care to augment physical care."
Before the Provet partnership, OOH case notes were sent to client practices which then had to enter them onto their systems manually.
Vidivet says the intregration with Provet means less admin and time savings for practices and a quicker follow up for pet owners.
https://vidivet.com
https://www.provet.cloud
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
Pet Anxiety Month aims to educate pet owners about the signs of anxiety in cats and dogs, help them identify the causes, and encourage them to take steps to support anxious pets (presumably by putting multiple diffusers in every home and blanketing large swathes of suburbia in a pea soup fog of pheromones).
Joking aside, the initiative comes on the back of the PDSA Animal Wellbeing report1 which revealed that over half of veterinary professionals think they've seen an increase in dog behavioural issues in the last two years, with over three-quarters of dog owners saying that they would like to change at least one behaviour displayed by their dog and nearly 90% of owners reporting that their cat is afraid of at least one thing.
To support the initiative, Ceva will be running a TV advertising campaign from 7 March until 21 April, which directly targets dog lovers during More4’s Crufts’ programmes (from 7 to 10 March).
The advertisements will also air on Channel 4, Channel 4 partner channels, Sky and Sky partner channels. Both advertisements are 30 seconds long.
Ceva is producing a marketing pack to raise awareness of Pet Anxiety Month containing eye-catching display materials and a social media toolkit.
Abigail King, Ceva's senior behaviour product manager, said: "More and more people are identifying anxiety and behavioural issues in their pets. Pet Anxiety Month will highlight signs of anxiety in cats and dogs that perhaps an owner is unaware of, help identify the problem and encourage changes both in and out of the home to make the household a happier place."
For further information, visit www.petanxiety.co.uk or Pet Anxiety Month on Instagram or Facebook.
Genitrix has extended its Dentagen dental care range with the addition of Dentagen Aqua, a water additive treatment to control plaque and prevent bad breath in cats and dogs.
Genitrix says the product offers a completely new approach to dental care for companion animals and is expected to prove particularly effective in treating cats which do not respond well to existing treatments, such as dental chews and tooth-brushing.
Dentagen Aqua is a palatable liquid which is added to a pet's drinking water on a daily basis. Its active principal is RF2, a plant extract. According to the company, RF2's ability to enable natural and healthy mouth bacteria to flourish while inhibiting the formation of plaque even at low concentrations has been demonstrated in extensive clinical trials. It operates as an 'anti-biofilm' treatment, modifying the growth of the membrane of oral bacteria to prevent them from producing plaque.
Dentagen Aqua is supplied in a 250 ml bottle costing £6.80. At the recommended dose of 5 ml per day, the bottle will provide 50 days' treatment for a cat or small dog.
In 2008, Genitrix launched the original Dentagen plaque protection system which consists of a unique RF2-impregnated wax provided to practices in a syringe to be applied to the gingival layer and the buccal area of teeth of dogs or cats at end of dental procedures. Dog owners can then maintain the protective coating by giving their pet Dentagen plaque prevention chews. The launch of Dentagen Aqua means that an equivalent solution is now available for cat owners or for dogs which don't eat chews.
With over 85% of dogs and cats over three years old suffering from some form of dental or gum disease, it's the most common health problem in these animals. The market for preventative dental healthcare supplements is estimated to be close to £1 million per annum.
Rob Watkins, Marketing Director at Genitrix, said: "Dentagen exceeded our expectations during its first year and has proved popular with both vets and dog owners. Given the vital importance of good dental health for dogs and cats, it seemed the logical next step to produce a water additive version to make the treatment easier for cat owners in particular."